Zometa Side Effects News
Urgent medical-dental alert for people who took
ZOMETA ®, FOSAMAX ®, or
AREDIA
®
These drugs
(Zometa, Fosamax, and Aredia)
have been linked to
the catastrophic condition(s)
“DEAD JAW” (Osteonecrosis of the jaw)
&
other severe conditions
If you or a loved one has been taking any of these “Bisphosphonates”
for Osteoporosis, Cancer or Multiple Myeloma & you have
experienced
complications, you must act now!
YOU MAY DESERVE COMPENSATION!
Contact today the offices of
Powell
Law Firm, L.C.
is the nation's leading law firm
for
litigation regarding Bisphosphonate Complications.
for your free,
confidential case evaluation
at toll-free 888-238-1998
Please state
your name and phone number
And we will
get back with you promptly
Accepting Inquiries from the U.S. and Internationally
Every case is different. No specific results are
implied.
269
South Beverly Drive, Suite 1156, Beverly Hills, CA 90212
|
Zometa,Aredia and Fosamax News Article Links |
| Fosamax and Zometa linked to jawbone death .or bone tumors. But about 10% were osteoporosis patients who had taken an oral bisphosphonate, mainly Fosamax. In May, Ruggiero ..News. |
| Fosamax ,Aredia
and
Zometa causes Jaw Problems .News..given bisphosphonates intravenously. Some patients take oral bisphosphonates, such as Fosamax and Zometa, for osteoporosis. The FDA acknowledges ... |
| Fosamax
and Zometa
Linked to Jaw Osteoporisis ..or Zoledronate/Zoledronic Acid ( Zometa ) therapy for malignancy, but several have occurred after oral treatment with Alendronate ( Fosamax,Zometa ) or Risedronate ... - Xagena.it |
|
Zometa
Side Effects |
|
Zometa
Attorney Information Zometa
Blog |
Fosamax ( generic name - Alendronate ) and Zometa are types of drugs known as bisphosphonates. Recently a link has been found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw ( ONJ ). This important discovery clearly shows that Fosamax side effects may include osteonecrosis of the jaw.
The discovery, published in the Journal of Oral and Maxillofacial Surgeons, prompted both the US, Food and Drug Administration ( FDA ) and Novartis, the manufacturer of bisphosphonates used in cancer chemotherapy, to issue a warning to health care professionals on September 24, 2004. The warning letter contained information about bisphosphonates and the risks of osteonecrosis in the jaw.
Bisphosphonates are commonly used in tablet form such as Fosamax ( Alendronate Sodium ) to prevent and treat osteoporosis in post-menopausal women. Stronger forms of bisphosphonates are commonly used in the management of advanced cancers that have metastasized to the bone, where the disease often causes bone pain and possibly even fractures. Several cancers can involve or metastasize to the bone, including lung cancer, breast cancer, prostate cancer, multiple myeloma, and others. When bisphosphonates are given in cancer chemotherapy, the drugs are given intravenously, and usually for longer periods of time.If you or a loved one have taken Fosamax or Zometa and have been injured as a result of Fosamax or Zometa side effects such as osteonecrosis of the jaw contact today the offices of
Powell Law Firm, L.C.
is the nation's leading law firm
for litigation regarding Bisphosphonate Complications.
for your free, confidential case evaluation
at toll-free 888-238-1998
Please state your name and phone number
And we will get back with you promptly
Accepting Inquiries from the U.S. and Internationally
Every case is different. No specific results are
implied.
269
South Beverly Drive, Suite 1156, Beverly Hills, CA 90212
.
.
Osteonecrosis of the Jaw
Osteonecrosis of the jaw ( ONJ ) is a condition in which the bone tissue in the
jaw fails to heal after minor trauma such as a tooth extraction, causing the
bone to be exposed. The exposure can eventually lead to infection and fracture
and may require long-term antibiotic therapy or surgery to remove the dying
bone tissue. Experts say that prevention and early treatment of individuals
using bisphosphonates such as Fosamax or Zometa is extremely important in preserving the
jaw bone. Individuals using Fosomax, Zometa or other bisphosphonates should attempt to
avoid tooth extractions and other major dental work while on the drugs.
Although most cases of osteonecrosis of the jaw related to Fosamax or Zometa
side effects
have occured after dental work several cases have been reported to occur
without any prior dental work. If you are currently taking Fosamax or Zometa
you may be
at risk of developing osteonecrosis. If you have been injured by Fosamax or
Zometa side
effects you may be entitled to compensation. For more information about your
legal rights contact the offices of
Powell
Law Firm, L.C.
is the nation's leading law firm
for
litigation regarding Bisphosphonate Complications.
for your free,
confidential case evaluation
at toll-free 888-238-1998
Please state
your name and phone number
And we will
get back with you promptly
Accepting Inquiries from the U.S. and Internationally
Every case is different. No specific results are
implied.
269
South Beverly Drive, Suite 1156, Beverly Hills, CA 90212
Zometa News Articles
IMF: Aredia and Zometa and osteonecrosis of the jaws A New Update ...
| ... finding was the apparent occurrence of jaw osteonecrosis in patients taking
bisphosphonates. ... How common is jaw osteonecrosis in myeloma patients? ... www.myeloma.org/main.jsp?type=article& tab_id=1&menu_id=0&id=1259 - 50k - |
ADRAC : bisphosphonates and osteonecrosis of the jaw
ABC News: Novartis Sees Jaw Damage in Cancer Drug Patients
... Novartis AG has received 875 reports of jaw problems in patients treated with two cancer drugs, but it ... sign the cases were related to the drugs, Zometa and Aredia. FDA officials urged further study to ...
- abcnews.go.com/Health/wireStory?id=552022
http://www.bethesda.med.navy.mil/careers/postgraduate_dental_school/research/clinical_updates/2005/0... (MICROSOFT WORD)
Osteoporosis Therapy Resources
MedWatch - 2005 Safety Information Alerts
... Report | Contact MedWatch Zometa (zoledronic acid) Aredia ... of osteonecrosis of the jaw (ONJ) observed in cancer patients ... disorders. Mislabeling problems with certain lots of this product ...
- www.fda.gov/medwatch/SAFETY/2005/safety05.htm
HKSTP - Healthcare News
Últimas novedades por revista
Drug Topics - Hot Off The Press
Surgery Press Releases
Health - Oral Health
Dental Amalgam and Mercury
FOX5 Las Vegas - Bisphosphonates Can Wreak Havoc in the Mouth and ...
| Bis-phossy jaw warrants the attention of oral and maxillofacial surgeons (OMSs)
and other health care professionals in part because bisphosphonate therapy ... www.kvvu.com/Global/story.asp?S=3305846 |
| Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the
21st century? J Oral Maxillofac Surg. 2005 May;63(5):682-9. ... www.dentalgentlecare.com/biop.htm |
| RESULTS: Descriptions of phossy jaw and current bis-phossy jaw cases are remarkably
... Histopathologic features of bis-phossy jaw showed intact vascular ... www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search& doptcmdl=Abstract&db=PubMed&orig_db=PubMed& |
| Bisphosphonate Osteochemonecrosis (Bis-Phossy Jaw): Is This Phossy Jaw of the
21st Century? / Hellstein, John W / Marek, Cindy L, 682-689 ... www.ucm.es/BUCM/compludoc/W/10505/02782391_2.htm |
| Bis-phossy jaw, Phosy Jaw and the 21st Century: Bisphosphonate Associated
Complications of the Jaws.” The Journal of Oral and Maxillofacial Surgery 62( 12): ... pharmacy.uiowa.edu/new/pharmreport/publications.htm
|
| ... of metastatic cancer may actually contribute to the onset of osteochemonecrosis,
or "bis-phossy jaw," a painful, potentially disfiguring jaw condition, ... surgery.advicepoint.net/ american-association-of-oral-maxillofacial-surgery/index.php |
Novartis Q4 misses forecasts, but R&D pleases Jan 20, 2005
Pharma
sales in 2004 were lifted by its Diovan hypertension medication,
Gleevec leukemia drug, Lamisil nail infection drug, Zometa intravenous
treatment for ... - Investor's Business Daily (subscription)
Improved Dosing Regimens and Novel Mechanisms of Action Drive ... Jan 18, 2005
...effective
in managing osteoporosis, the introduction of bisphosphonates with
monthly and yearly dosing regimens in the form of Boniva and Zometa is
likely to ... - Business Wire (press release),
Schering Cancer Drug Faces US Delay Jan 7, 2005
Novartis's
rival product Zometa, for example, had sales of nearly $900 million in
2003, of which two-thirds was in the United States. - MSN Money
New Clinical Trial Initiated to Evaluate QUADRAMET(R) in ... Jan 11, 2005
...from
a single arm phase II trial conducted by independent investigators in
Europe that evaluated the efficacy of QUADRAMET and zoledronic acid
(Zometa(R) by ... - ArriveNet (press release),
Doctors Link Common Chemotherapy Drug To Jawbone Necrosis Dec 30, 2004
December
16, 2004) -- Novartis has notified healthcare professionals about new
precautions for the company's two bisphosphonate drugs, Zometa
(zoledronic acid ... - Science Daily (press release)
NEW STUDY RESULTS SHOW ABILITY OF ZOMETA TO DELAY ONSET OF ... Sep 1, 2003
Novartis AG’s Zometa (zoledronic acid) demonstrated significant clinical benefit
in a placebo-controlled study published in the Sept. 1 issue of Cancer. ... (Pharmexec (press release))
Novartis: bisphosphonate study should boost Zometa sales Sep 2, 2003
With Novartis' [NVS] Zometa recently gaining a sNDA for patients with bone metastases
from advanced malignancies and this class of adjunct therapy becoming ... (UK Comment Wire, UK)
Community hospitals enter field of drug trials Sep 15, 2003
Zometa, a second drug in the study, is being tested for its effectiveness
in preventing osteoporosis in women taking hormone blockers. ... (Arkansas Democrat Gazette, AR)
http://www.johnthreadgill.com/sitemap.htm